First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based ...
Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...
With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough ...
Hundreds of Boston residents and some Boston University students who ended up in the emergency room with the norovirus this winter may take comfort in a recent research breakthrough that may help ...
Moderna's mRNA-1273 vaccine helped prevent medically attended COVID-19 and related hospitalizations across multiple respiratory seasons among adults.
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...
New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback